🆕 breast cancer treatment recommended Our final guidance recommending capivasertib with fulvestrant for treating hormone receptor-positive HER2-negative advanced breast cancer after endocrine treatment has been published today. Read the guidance here: https://www.nice.org.uk/guidance/ta1063?utm_medium=organic&utm_source=whatsapp&utm_campaign=capivasertib_150525&utm_content=quotegraphic